Ivax Signs Amended Distribution Agreement With Immco

Ivax has signed an amended distribution agreement with Immco. The agreement provides Diamedix rights to distribute Immco’s portfolio of products in the US, with additional strategic initiatives related to the US and Canadian market to follow.

The products, to be distributed by Diamedix, include 60 Autoimmune ELISA (Enzyme-Linked Immunosorbent Assay) test kits, an increase from the current 25 autoimmune test kits currently distributed by Diamedix, and 150 IFA (Immunoflourescence Assays) test kits.

The products will initially be marketed under the name of Immco to accelerate market introduction, and in the beginning of 2010, it will be sold under the Diamedix brand.

Charles Struby, CEO of Ivax, said: “Immco’s collaboration with a number of prominent researchers and distinguished institutions help to produce new technologies for the marketplace. We believe the combined strength of Diamedix’ sales force and Immco’s reputation as a premier manufacturer of test kits, will provide a strong suite of products and viable solutions for customers as Ivax strives to become their sole source of infectious disease and autoimmune invitro diagnostic testing. This agreement alone will substantially increase the number of ELISA and IFA test kits we offer.”

“Part of our goal is to introduce new analyzer instrumentation accommodating both ELISA and IFA test kits in the US market. Immco’s test kits will be compatible with the new instrumentation, allowing interchangeability of test formats, thereby reducing the manual effort currently involved with IFA testing. Our agreement with Immco will help to strengthen our mission to create a stronger and more competitive company by distributing test kits that meet and/or exceed patients’ and their physicians’ needs for accurate and efficient in vitro diagnosis,” he added.